Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature
暂无分享,去创建一个
[1] B. Egan,et al. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.
[2] S. Oparil,et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension , 2009, Journal of hypertension.
[3] W. Elliott. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events , 2009 .
[4] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[5] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[6] J. Staessen. Blood pressure lowering for the primary and secondary prevention of stroke (OR07-02) , 2008 .
[7] C. Mathers,et al. Preventing stroke: saving lives around the world , 2007, The Lancet Neurology.
[8] J. Staessen,et al. Oral renin inhibitors , 2006, The Lancet.
[9] Li-sheng Liu,et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients , 2005, Journal of hypertension.
[10] Fan Wu,et al. Preventing chronic diseases in China , 2005, The Lancet.
[11] J. Staessen,et al. Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention , 2005, Hypertension.
[12] A. Hofman,et al. The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients , 2005, Blood pressure.
[13] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[14] F. Messerli,et al. Do thiazide diuretics confer specific protection against strokes? , 2003, Archives of internal medicine.
[15] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[16] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[17] A. Hofman,et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.
[18] Jing Chen,et al. Prevalence, Awareness, Treatment, and Control of Hypertension in China , 2002, Hypertension.
[19] J. Bosch,et al. Use of ramipril in preventing stroke: double blind randomised trial , 2002, BMJ : British Medical Journal.
[20] O. Godefroy,et al. Age-adjusted stroke incidence increase: could angiotensin AT1 receptor antagonists enhance stroke prevention? , 2002, Stroke.
[21] Johan P Mackenbach,et al. Income inequality and population health , 2002, BMJ : British Medical Journal.
[22] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[23] D. Johnston. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.
[24] J. Achard,et al. Journal of Renin-angiotensin-aldosterone System Journal of Renin-angiotensin-aldosterone System Non-at1-receptor-mediated Protective Effect of Angiotensin against Acute Ischaemic Stroke in the Gerbil Journal of Renin-angiotensin-aldosterone System Additional Services and Information for Journal of t , 2022 .
[25] B. Neal. The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .
[26] S. MacMahon,et al. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. , 2000, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[27] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[28] S. Yusuf,et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .
[29] Jin-Moo Lee,et al. The changing landscape of ischaemic brain injury mechanisms , 1999, Nature.
[30] H. Schunkert,et al. β Adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics , 1998, Heart.
[31] D. Murphy,et al. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies , 1995, The Lancet.
[32] Pats-Collaborating-Group-. Post-stroke antihypertensive treatment study. A preliminary result , 1995 .
[33] B. Olofsson,et al. Atenolol in Secondary Prevention after Stroke , 1995 .
[34] L. Wilkins. Trial of Secondary Prevention With Atenolol After Transient Ischemic Attack or Nondisabling Ischemic Stroke , 1993, Stroke.
[35] F. Brackman,et al. Cardiovascular protective properties of indapamide. , 1990, The American journal of cardiology.
[36] J. Savineau,et al. Effect of indapamide on the electromechanical properties of rat myometrium and rat portal vein. , 1986, The Journal of pharmacology and experimental therapeutics.
[37] R Peto,et al. Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.
[38] R. N. Brogden,et al. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. , 1984, Drugs.
[39] J. Savineau,et al. Compared effects of indapamide, hydrochlorothiazide and chlorthalidone on electrical and mechanical activities in vascular smooth muscle. , 1981, European journal of pharmacology.
[40] A. Carter,et al. Hypotensive therapy in stroke survivors. , 1970, Lancet.
[41] L. Kong,et al. Chronic Diseases 4 Preventing chronic diseases in China , 2022 .